Axxin provides platforms and diagnostic products for biomedical applications that bridge
the gap from research to market with world leading innovation, capability and cost effectiveness.
The company's goal is to take the cost and complexity out of point of care diagnostics and near patient applications. The company has extensive experience in instrument design, industrial design, sensor technologies and has applied these to molecular and lateral flow applications.
Axxin has established itself as an early leader in commercialising diagnostic delivery systems in partnership with leading biomedical and pharmaceutical companies.
Molecular Medicine Tri-Conference, produced by Cambridge Healthtech Institute, is the predominant event on the West Coast focused on integrating the entire spectrum of drug development. CHI's Molecular Medicine Tri-Conference event is unique in that it brings together the therapeutic and diagnostic aspects of the industry in one place.
Conference is located at the Hilton San Diego Bayfront.
Come and meet Axxin's Nathan Butlin, VP Strategy & Alliances, and Andrew Lysikatos, Axxin CEO at booth 200.